Global TB Vaccines Market Size By Type (Mobile, Benchtop), By Application (For Water Analysis, Measuring), By Region, And Segment Forecasts, 2023 to 2032

The Global TB Vaccines Market was valued at USD 1.3 billion in 2023 and is projected to surpass USD 3.6 billion by 2031, growing at a CAGR of 13.5% during the forecast period of 2023 to 2031. The increasing global burden of tuberculosis (TB), coupled with the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, is propelling the need for effective vaccines. Governments and global health organizations are investing heavily in TB prevention strategies, and vaccine development is at the forefront of these initiatives. Rising awareness, increased funding for TB research, and new technological advancements in immunology and vaccine delivery systems are accelerating market growth.

Drivers

1. Growing Global Burden of TB

Despite being preventable and treatable, TB remains one of the leading causes of death from a single infectious agent globally. The World Health Organization estimates over 10 million new cases annually, creating an urgent need for effective vaccination programs.

2. Emergence of Drug-Resistant TB Strains

The rise in MDR and XDR TB has made existing treatment regimens less effective, placing greater emphasis on the development and deployment of new vaccines to prevent the spread of resistant strains.

3. Robust Funding and Public Health Initiatives

Global organizations like the WHO, GAVI, and the Bill & Melinda Gates Foundation are supporting TB vaccination through funding and policy advocacy, bolstering research and early-stage vaccine trials.

Restraints

1. Long and Costly Vaccine Development Process

Developing new TB vaccines involves complex clinical trials and extended timelines, often resulting in significant R&D costs. This poses a challenge for smaller biotech firms.

2. Regulatory Hurdles

Vaccines must meet stringent regulatory standards, and obtaining approval across various countries can delay market entry, particularly in low-income regions where TB prevalence is highest.

Opportunity

1. Technological Advancements in Vaccine Platforms

Innovations in mRNA technology, viral vector platforms, and adjuvant systems present new opportunities to develop more effective TB vaccines with higher efficacy and fewer side effects.

2. High Demand in Endemic Regions

Asia-Pacific and Sub-Saharan Africa, where TB prevalence remains high, offer a vast untapped market. Strengthening public-private partnerships in these regions can significantly boost adoption.

Market by System Type Insights

Based on vaccine type, the Live Attenuated Vaccines segment accounted for the largest market share in 2023, driven by the continued use of Bacillus Calmette-Guérin (BCG) vaccines. However, the Subunit and Recombinant Vaccine segment is expected to register the fastest growth, owing to promising candidates in clinical pipelines like M72/AS01E and VPM1002, which are demonstrating improved immunogenicity.

Market by End-use Insights

By end-use, the Pediatric Vaccination Programs segment dominated the market in 2023 due to widespread inclusion of BCG in national immunization schedules for infants. Meanwhile, Adult and Adolescent Immunization Programs are expected to witness rapid expansion during the forecast period, especially in high-burden countries, supported by new clinical evidence and pilot programs targeting older age groups.

Market by Regional Insights

Geographically, Asia-Pacific held the largest share of the TB vaccines market in 2023, driven by the high incidence of TB in countries like India, China, Indonesia, and the Philippines. North America and Europe are investing significantly in vaccine R&D, while Africa is anticipated to be the fastest-growing regional market due to global partnerships and aid-supported immunization programs.

Competitive Scenario

Key players in the global TB vaccines market include Serum Institute of India, GlaxoSmithKline plc, Aeras (a non-profit biotech), Statens Serum Institut, Biofabri, Sanofi, and GreenSignal Bio Pharma Ltd. These companies are focused on strategic collaborations, clinical trials, and innovative delivery mechanisms to bring next-generation TB vaccines to market.

Key Developments:

In 2023, GSK and Aeras reported positive Phase IIb results for the M72/AS01E TB vaccine candidate in adults.

In 2024, Serum Institute of India began Phase III trials for VPM1002, a genetically modified BCG replacement.

In 2025, Biofabri received fast-track designation from regulatory authorities for its TB vaccine MTBVAC in Europe.

Scope of Work – Global TB Vaccines Market

FAQs

1) What is the current market size of the Global TB Vaccines Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global TB Vaccines Market?

The primary growth driver is the increasing global burden of tuberculosis and the need for more effective vaccines.

3) Which is the largest region during the forecast period in the Global TB Vaccines Market?

Asia-Pacific is projected to remain the largest regional market due to its high TB prevalence and government vaccination initiatives.

4) Which segment accounted for the largest market share in the Global TB Vaccines Market?

The Live Attenuated Vaccines segment held the largest share in 2023, largely due to continued BCG vaccine use.

5) Who are the key market players in the Global TB Vaccines Market?

Key players include Serum Institute of India, GlaxoSmithKline plc, Aeras, Biofabri, Statens Serum Institut, and Sanofi.